FIELD: biotechnology.
SUBSTANCE: invention relates to novel conjugates of a site-specific antibody with a cytotoxic agent, wherein the cytotoxic agent is covalently bonded to one or more cysteine residues of the antibody. Present invention further provides a composition and methods suitable for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of this invention.
EFFECT: conjugates of engineered antibodies with cysteine substitutions are disclosed.
25 cl, 8 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATES OF ENGINEERED ANTIBODIES WITH CYSTEINE SUBSTITUTES | 2016 |
|
RU2733740C2 |
| MAITANZINOID DERIVATIVES WITH SELF-SPLITTING PEPTIDE LINKERS AND THEIR CONJUGATES | 2018 |
|
RU2765098C2 |
| BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | 2020 |
|
RU2832083C2 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS | 2017 |
|
RU2766959C2 |
| ANTI-FcRH5 ANTIBODIES | 2014 |
|
RU2687132C2 |
| DOSAGE MODE OF PTH COMPOUND OF CONTROLLED RELEASE | 2017 |
|
RU2777357C2 |
| METHODS FOR PREPARING ANTIBODY-DRUG CONJUGATE COMPOSITIONS | 2015 |
|
RU2741470C2 |
| CONJUGATE OF TROP-2 ANTIBODY AND EXATECAN ANALOGUE AND MEDICAL USE THEREOF | 2021 |
|
RU2830167C1 |
| ERIBULIN DERIVATIVE DRUG CONJUGATE, METHOD FOR PREPARATION THEREOF AND USE THEREOF IN MEDICINE | 2021 |
|
RU2830242C1 |
